Programme

Wednesday Feb 12th

18.00-20.00 Welcome reception Cancer Center Karolinska, Floor 5

Thursday Feb 13th, venue Sune Bergström auditorium at Bioclinicum, Karolinska University Hospital, Solna   

 

07.45- Registration at Bioclinicum, outside of Sune Bergström  auditorium.
08.20-08.30 Welcome, information

Immunotherapy

Chair: Eric Raymond, University of Paris 

08.30-09.00

Rolf Kiessling, Karolinska Institutet

Immune therapy of cancer; recent advances and challenges

09.00-09.30

This session has been sponsored by MSD

Pedro Farrajota Neves da Silva, Karolinska University Hospital

 From lab bench to bedside:

 Immunotherapy in head and neck squamous cell carcinoma (HNSCC) 

09.30-09.55

Per Straten, University of Copenhagen

The exercise of TAMing the immune system

09.55-10.15 Coffee break

Breast cancer

Chair:  Andrea Bonetti, Mater Salutis Hospital Legnago (Verona, ITALY) and  Giovanni Codacci-Pisanelli, University of Rome

10.15-10.40

Jonas Bergh, Karolinska Institutet

General overview of breast cancer with special attention to prognostication and prediction during tumour progression

10.40-11.05

Charlotta Dabrosin, Linköping University

The inflammatory microenvironment affects breast cancer progression

11.05-11.30

Theo Foukakis, Karolinska Institutet

Deciphering the role of immune microenvironment in breast cancer: expression patterns, prognostic/predictive value and therapeutic implications

11.30-12.00

Presentation of selected abstracts

Santiago Parpal, Sprint Bioscience

Modulation of the tumor inflammatory landscape by Vps34 inhibitors as basis for combination immunotherapy

Margot S.F. Roeten, Amsterdam UMC

Evaluation of the proteasome inhibitor Ixazomib effectivity against primary pediatric acute leukemia cells and Bortezomib-resistant leukemia cells

12.00-12.45 Lunch

Ovarian cancer and Prostate cancer

Chair:  Paola Perego, Instituto Tumori, Milan

12.45-13.10

Filippo Cortesi, University Medical Center Hamburg, Eppendorf

Tumor-specific iNKT cell plasticity – Prostate versus Colon

13.10-13.35

Sten Nilsson, Karolinska Institutet

Treatment of disseminated prostate cancer

13.35-14.00

Martina Bazzaro, University of Minnesota

Novel strategies for treatment of late stage ovarian cancer

14.00-14.25

Paula Cunnea, Imperial College, London

Novel approaches to personalised therapy for epithelial ovarian cancer

14.25-14.55 Coffee break

Individualised therapy

Chair: Rolf Lewensohn, Karolinska Institutet

14.55-15.25

Jan-Olov Sandberg, Roche

Implementation of precision medicine in oncology – challenges and opportunities

15.25-15.50

Andrea Bonetti, Mater Salutis Hospital Legnago (Verona, ITALY)

Next generation sequencing in clinical diagnosis

15.50-16.15

Tríona Ní Chonghaile, Royal College of Surgeons in Ireland, Ireland

BH3 profiling to functionally interrogate cell death pathways and identify combination treatments

16.15-16.40

Bo Franzén, Karolinska Institutet

Molecular diagnostics using fine needle tumour aspirates for cancer treatment decisions

16.40-17.05

Joseph Ciccolini, University of Marsielle

Improving PK/PD profiles of anticancer agents with nanoparticles

19.00- 21.00

Conference dinner, Restaurant Solliden, Skansen,

Transfer bus departs at 18.15 from Elite Hotel Carolina Tower and has a pick-up at Elite Hotel Palace.

Transfer bus back to the Elite hotel Carolina Tower and Elite hotel Palace at 21:15

 

 Friday Feb 14th

  


DNA repair 
Chair: Frits Peters, University Medical Center, Amsterdam
08.30-08.55

Thomas Helleday, Karolinska Institutet

MTHFD2, targeting the DDR at the crossroad of metabolism

08.55-09.20

Vincenzo Costanzo, Fondazione Istituto FIRC, Milan

Understanding and treating DNA repair and replication defects due to BRCA1/2 deficiency

09.20-9.45

Duncan Jodrell, University of Cambridge

Synergy between ATR Inhibitors and Gemcitabine to Induce Pancreatic Ductal Adenocarcinoma Regression

09.45-10.15 Coffee break

Novel therapeutics

Chair: Etienne Chatelut, Institut Universitaire du Cancer Toulouse- Uncopole

Padraig D´arcy, Linköping University

10.15-10.35

This session has been sponsored by Astra Zeneca

Simon Ekman, Karolinska Institutet

Clinical activity and resistance mechanisms of osimertinib in patients with EGFR-mutated advanced NSCLC

10.35-11.00

Elias Arnér, Karolinska Institutet

The selenoprotein thioredoxin reductase as target for cancer therapeutics

11.00-11.25

Lars-Gunnar Larsson, Karolinska Institutet

Selective targeting of the interaction between MYC and MAX

11.25-11.50

Klas Wiman, Karolinska Institutet

Pharmacological reactivation of mutant p53

11.50-12.10

Presentation of selected abstracts

Mjriam Capula, Pisa Science Foundation

Role of miRNA-21 and YAP in mechanical memory and chemoresistance of pancreatic cancer cells 

Sean Rudd, Karolinska Institutet

Targeting SAMHD1 to enhance existing cancer therapies

 12.10-13.00 Lunch

Tumor Models

Chair: Elisa Giovanetti, University Medical Center, Amsterdam

13.00-13.25

Oded Kopper, Hebrew University of Jerusalem

Novel ovarian cancer organoid platforms for research and personalized medicine

13.25-13.50

Mårten Fryknäs, Uppsala University

Multicellular tumor cultures and identifcation of context – dependent vulnerabilities

13.50-14.15

 

Leoni Kunz Schughart, Technical University, Dresden

Using the spheroid control probability assay for combination therapy

14.15-14.40

Martin Michaelis, University of Kent

Drug-induced heterogeneity associated with acquired resistance formation

14.40-15.00 Coffee break

Head and Neck cancer

Chairs: Tina Dalianis, Karolinska Institutet

Eva Munck af Rosenschöld-Wikland, Karolinska Institutet

15.00-15.25

Paolo Bossi, University of Brescia (EORTC-Head&Neck Group)

Looking for new combinations for immunotherapeutics in head and neck cancer

15.25-15.50

Rieneke van der Ven, VUmc, Amsterdam

Immunology and head and neck cancer: from bench to bedside

15.50-16.15

Laura Locati, Istituto Nazionale dei Tumori, Milan (EORTC-Head & Neck group)

Immunoheterogeneity of HPV-related oropharynx cancer and patients’outcome

16.15-17.05

Presentation of selected abstracts

Farina Hellmann, University of Muenster

External Model Validation of a Population Pharmacokinetic Model for Doxorubicin in a Cohort of Ewing Sarcoma Patients

Ariane Rocha Bartolomeu, São Paulo State University

The effects of major bioactive coffee compounds against mouse colon carcinogenesis: miRNA profile modulation

Emilie Vinolo, Science SPRL

The EurOPDX Research Infrastructure: improving and facilitating European and worldwide cancer research with patient-derived xenografts

Timothy Isaac Johnson, University of Cambridge

Quantifying cell cycle-dependent drug sensitivities: combining a novel synchronisation method with high-throughput screening

 17.05-  POSTER VIEWING, catering

 

Saturday Feb 15th 

  

Medicinal Chemistry

Chairs: Andrew Westwell, University of Cardiff

Georg Hempel, University of Münster

09.00-09.25

Caroline Low, Drug design consultant, London, UK

Using open source tools for kickstarting MAP4K4 drug discovery – lessons learnt

09.25-09.50

Johannes Kirchmair University of Vienna, Vienna

PAIN(S) relievers for pharmacologists: How in silico tools can help to flag compounds that are prone to cause false outcomes in biological assays

09.50-10.15

Barbara Parrino, University of Palermo

Marine alkaloid analogs as valuable tools to fight cancer

10.15-10.30

Markus Joerger, Department of Medical Oncology & Hematology, Cantonal Hospital, Switzerland

Safety and pharmacokinetics of a novel nano-sized micellar formulation of docetaxel

10.30-10.45 Coffee break
10.45-11.10

 Per Artursson, Uppsala University

Impact of intracellular unbound drug concentration on target engagement, pharmacological response and drug-drug interactions

11.10-11.35

Christian Rolfo, University of Maryland School of Medicine

Liquid biopsies 

11.35-12.20

Burger-Kelland lecture

Nadia Zaffaroni and Paola Perego, Istituto Tumori, Milan

12.20-12.30 Poster prize and closure

 

 

 

 

 

 

 

 

 

 

 

Contact

Academic Conferences - Universities in cooperation Karolinska Institut, SLU and Uppsala University

Mail: Pamm2020@akademikonferens.se

Phone +46 18-67 20 59 or + 18-67 10 03